A Phase 3 Study of UGN-102 for Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Clinical trial NCT04688931 · TERMINATED

Trial details

NCT number: NCT04688931
Sponsor: UroGen Pharma Ltd.
Status: TERMINATED
Phase: Phase 3
Study type: INTERVENTIONAL

Bladder Cancer Urothelial Carcinoma Urothelial Carcinoma Bladder

Start date: 2021-02-19
Primary completion: 2023-03-17
Enrollment: 282

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.